Combining Fasting and Fibre Interventions to Optimise Their Gut Microbiome-mediated Health Benefits

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBuchinger Wilhelmi Development & Holding GmbH

About this trial

This study builds on the knowledge that fasting provides metabolic health benefits and that prebiotic interventions can enhance the gut microbiome's metabolic output to likewise improve host health. Whether long-term fasting and dietary fibre interventions could be combined to achieve synergistic improvements in host metabolic health is however unknown. The goal is to provide a proof of concept in a human trial that supplementing 10±4 days fasting with dietary fibre synergistically improves metabolic outcomes via gut microbiome-mediated effects. To assess this, we aim to analyse gut microbiome changes, functional outputs, and key metabolic markers such as butyrate production, glycaemic control and ketosis.

The randomised controlled trial includes 75 participants and has two arms: one involving fasting with fibre supplementation (n = 50) and one involving fasting without fibre supplementation (n = 25). All participants will undergo a fasting period of 10±4 days according to the Buchinger Wilhelmi protocol, followed by a stepwise reintroduction of food of up to 4 days. As dietary fibre we will use maize-derived resistant starch type IV, selected based on its ability to stimulate beneficial gut microbes like Oscillibacter and corn starch as placebo. Two main visits will be conducted: before and at the end of the fasting period. During these visits, blood and stool samples will be collected, and questionnaires will be completed. Additionally, daily measurements of anthropometric parameters and well-being will be recorded. Stool samples will also be collected one month afterwards as a follow-up. Participants' metabolic health will be evaluated through various clinical parameters (e.g., body measurements, blood pressure, glycaemic control, ketones, well-being). Additionally, multi-omics data, including metagenomics and metabolomics, will provide insight into the composition of the microbiome, as well as its outputs and functions. Furthermore, the effects of fasting on extracellular vesicles in blood will be explored.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Men and women

Age: 18-65 years old

Fasting for 10±4 days at the Buchinger Wilhelmi clinic in Überlingen

BMI ≥ 25 kg/m²

Disqualifiers

intake of antibiotics up to 2 months prior the study

regular intake of pre-, post- and probiotics up to 2 months prior the study

diagnosed Crohn's disease, Ulcerative colitis, IBD, coeliac disease

medicated high blood pressure

Trial design

Design model

Parallel

Treatments tested in this trial

  • Fibre Arm

    Dietary supplement

    10±4 days of fasting according to the Buchinger Wilhelmi fasting protocol, followed by a structured food reintroduction period, combined with 20 g/day of maize-derived resistant starch type IV.

  • Control Arm

    Dietary supplement

    10±4 days of fasting according to the Buchinger Wilhelmi fasting protocol, followed by a structured food reintroduction period, combined with 1.2 g/day of corn starch placebo.

Treatment groups

75 Participants
are divided into 2 treatment groups
Group A: Fibre ArmActive comparator 1 intervention
Group B: Control ArmPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Abundance of butyrate-producing gut bacteria

Change in the relative abundance of butyrate-producing gut bacteria assessed by metagenomic profiling of faecal samples.

Time frame
Baseline (T0) and end of the 10±4-day fasting period (T1)
2

Change in fasting venous plasma glucose

Fasting venous plasma glucose concentration measured by clinical laboratory analysis (mmol/L).

Time frame
Baseline (T0) and end of the 10±4-day fasting period (T1)

Secondary outcomes

1

Change in body weight

Body weight (kg) measured as part of the clinical health assessment.

Time frame
Baseline (T0) and end of the 10±4-day fasting period (T1)
2

Change in body mass index

Body mass index calculated from measured body weight and height (kg/m²).

Time frame
Baseline (T0) and end of the 10±4-day fasting period (T1)
3

Change in waist circumference

Waist circumference (cm) measured as part of the clinical health assessment.

Time frame
Baseline (T0) and end of the 10±4-day fasting period (T1)
4

Change in HbA1c

HbA1c (mmol/mol) measured by clinical laboratory analysis of venous blood.

Time frame
Baseline (T0) and end of the 10±4-day fasting period (T1)

Other outcomes

1

Change in the abundance of butyrate-producing gut bacteria

Exploratory assessment of the change in the abundance of butyrate-producing gut bacteria, derived from metagenomic profiling. Additional unscheduled samples may be collected during fasting if spontaneous bowel movements occur.

Time frame
Baseline (T0), end of the 10±4-day fasting period (T1), and 1 month after fasting (T2)
2

Change in body weight

Exploratory assessment of change in body weight (kg)

Time frame
Baseline (T0), daily during the 10±4-day fasting period and food reintroduction period, and 1 month after fasting (T2)
3

Change in body mass index

Exploratory assessment of change in body mass index (kg/m²).

Time frame
Baseline (T0), daily during the 10±4-day fasting period and food reintroduction period, and 1 month after fasting (T2)
4

Change in glycaemic control assessed by continuous glucose monitoring

Exploratory assessment of change in glycaemic control during the post-fasting follow-up period, assessed by open-label continuous glucose monitoring.

Time frame
From day 15 through day 28

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Buchinger Wilhelmi Development & Holding GmbH

Lead sponsor

King's College London, Faculty of Life Sciences & Medicine, Department of Nutritional Sciences, London, United Kingdom

Collaborator

Leiden University Medical Center, Department Leiden University Center for Infectious Diseases, 2333ZA, Leiden, Netherlands

Collaborator

TNO, Department Microbiology & Systems Biology, 2333 BE Leiden, Netherlands

Collaborator

Università degli Studi di Milano, Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti, Milan, Italy

Collaborator

Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

Collaborator